GALDERMA
23.5.2024 07:01:27 CEST | Business Wire | Press release
Galderma (SWX:GALD) announced today the launch of its hyaluronic acid injectable filler, Restylane® VOLYME™ in China. The company is also introducing its complementary Shape Up Holistic Individualized Treatment (HIT™) in the country, which addresses aging concerns caused by loss of structural support in the mid-face. The availability of these targeted solutions for the mid-face region is demonstrative of Galderma’s commitment to meeting patient and injector needs in China. In the past decade, the growth of China’s aesthetics medicine market has outpaced the global market; with relatively low market penetration, there remains significant potential for future growth.1
Developed using Galderma’s proprietary OBT™* gel technology, Restylane® VOLYME™ is indicated for the correction of mid-face volume deficit and/or mid-face contour deficiency through injections into the subcutaneous to supraperiosteal layers of the skin.2-3 Hyaluronic acid fillers are often patients’ first choice for mid-face augmentation and have been shown to deliver high patient satisfaction and long-lasting effects.4 In China, hyaluronic acid fillers are among the top 10 most-sold aesthetics products.1
“We are delighted to deliver Galderma’s innovative aesthetics solutions in China with the support of our research and development teams, as well as local partners and regulatory authorities. As the Chinese market continues to expand, we look forward to working closely with all stakeholders to deliver our full, premium range of aesthetics products to meet the varied and individual needs of patients and injectors.”
GERRY MUHLE
|
|
Developed with a global community of injectors, the Shape Up HIT™ is the latest of Galderma’s HITs™ to be introduced in China, designed to create a common language to facilitate a two-way dialogue between patient and practitioner to align on patient priorities and keep satisfaction at the forefront.
"Aesthetic plastic surgery is an artistic creation under medical constraints, embodying a holistic and individualized approach. Facial expressions are controlled by 42 muscles which convey emotions such as joy, anger, sorrow, and happiness. These muscles are also involved in language, chewing, and other activities. The appearance of the mid-face is crucial in interpersonal communication. Together, Restylane® VOLYME™ and the Shape Up HIT™ enable patients to maintain their natural facial expressions while also supporting injectors to deliver a youthful and long-lasting aesthetic effect."
PROFESSOR HAIYAN CUI
DIRECTOR OF THE PLASTIC & COSMETIC SURGERY DEPARTMENT
|
|
HIT™ is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane® portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction. The Balanced Profile HIT™ was Galderma’s first HIT™ to be introduced in China in 2023, providing a framework for practitioners to conduct a full objective facial assessment for the patient and help bring balance to their profile. HIT™ naturally springboards from Galderma’s AART™ (Assessment, Anatomy, Range, Treatment) methodology for a new generation of individualized aesthetics.
Restylane® is the largest and most diverse range of individually engineered hyaluronic acid fillers on the market, approved in more than 80 countries and regions, and with over 65 million treatments administered worldwide.5-8
About Galderma
Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
Notes and references:
* Optimal Balance Technology – OBT
- Deloitte. China Aesthetic Medicine Outlook Report. Accessed May 2024. Available online.
- Talarico S et al. High patient satisfaction of a hyaluronic acid filler producing enduring full-facial volume restoration: An 18-month open multicenter study. J Dermatol Surg. 2015; 41: 1361-1369.
- Galderma. Restylane Instructions for Use.
- Trinh LN & Gupta A. Hyaluronic acid fillers for midface augmentation: A systematic review. Facial Plast Surg. 2021; 37(5): 576-584.
- Öhrlund A. New method to study the balance of firmness and flexibility for HA fillers. Poster presented at AMWC 2019.
- Galderma. Data on file. MA-57232.
- Galderma. Data on file. MA-33939.
- Galderma. Data on file. QMS-3637.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522425104/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom